GNI Group Ltd 2160
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥2,266.00
- Day Range
- ¥2,165.00–2,361.00
- 52-Week Range
- ¥2,003.00–3,740.00
- Bid/Ask
- ¥2,291.00 / ¥2,292.00
- Shares Outstanding
- 65.81M
- Market Cap
- ¥150.85B
- Volume/Avg
- 4M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 299.16
- Price/Sales
- 3.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases. The company's business activities are divided into the pharmaceutical business and the medical device business. In the pharmaceutical business, the company conducts research and development, manufacturing, and sales of development compounds, mainly I-Suru, which is sold in the Chinese market, and F351, which has completed clinical trials. In the medical device business, the company develops, manufacture, and sell medical devices (biomaterials) based in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,040
- Website
- https://www.gnipharma.com
Valuation
Metric | 2160 |
|---|---|
Price/Earnings (Normalized) | 299.16 |
Price/Book Value | 2.32 |
Price/Sales | 3.55 |
Price/Cash Flow | — |
Price/Earnings
2160
Financial Strength
Metric | 2160 |
|---|---|
Quick Ratio | 1.07 |
Current Ratio | 1.54 |
Interest Coverage | −1.28 |
Quick Ratio
2160
Profitability
Metric | 2160 |
|---|---|
Return on Assets (Normalized) | −5.02% |
Return on Equity (Normalized) | −10.53% |
Return on Invested Capital (Normalized) | −4.84% |
Return on Assets
2160
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<XWLpl | LOCK|xxTh | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^>&qSW< | LOCK|>FZ$? | $99B | |||
| Moderna Inc MRNA | LOCK|GQ&<&< | LOCK|%^M | $87B | |||
| argenx SE ADR ARGX | LOCK|&G?RvC | LOCK|%PJ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&bK>Mb! | LOCK|$% | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Q^$y#pR | LOCK|%CvY# | $31B | |||
| Incyte Corp INCY | LOCK|W%#@tV | LOCK|>kC | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|m&>?>#b | LOCK|#?mnP | $21B | |||
| BioNTech SE ADR BNTX | LOCK|L$!S^$d | LOCK|XZj | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$>G?#C | LOCK|q^ | $15B |